In multiple myeloma (MM), limited activity has been observed with anti-CD19 CAR-T cells due to the low antigen expression on plasma cells, but encouraging results and good tolerability have been observed in clinical trials with anti-CD138 and anti-BCMA CAR-T cells in R/R MM [36,37]. This evidence concerns the gene CD19 and Miyoshi myopathy.